High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

NCT01896271 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG: IL-2
RADIATION: Stereotactic Ablative Body Radiation Therapy

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]